| Deal value | $144M |
|---|---|
| Share of market cap | 18.4% |
Key highlights
- Offering of 35,714,286 shares of common stock priced at $3.50 per share
- Underwriters granted a 30-day option for an additional 5,357,142 shares
- Estimated net proceeds of $134.7 million after commissions and expenses
- Primary funding targets include Wilson disease and alpha-1 antitrypsin deficiency programs
- Joint book-running managers include Jefferies, TD Securities, and Goldman Sachs
What Is the Capital Raise?
Prime Medicine has finalized an underwriting agreement with a syndicate led by Jefferies LLC, TD Securities, and Goldman Sachs for the sale of 35,714,286 shares of common stock. The offering is priced at $3.50 per share, which represents a discount to the recent trading price of $4.30. Additionally, the company has provided underwriters with a 30-day option to purchase up to 5,357,142 additional shares to cover over-allotments. If exercised in full, the total gross proceeds from the capital raise will reach approximately $143.75 million. The offering is expected to close on or about November 12, 2026, subject to customary closing conditions.
Use of Proceeds
- Advancement of the Wilson disease clinical program through early-stage development
- Support for the alpha-1 antitrypsin deficiency research and development pathway
- Funding for broader research and development activities involving Prime Editing
- Allocation for essential capital expenditures and general corporate overhead
- Strengthening of working capital to maintain operational flexibility for pipeline milestones
Strategic Rationale
This capital infusion allows Prime Medicine to secure its financial runway during a period of intensive research and development. By leveraging a shelf registration statement, the company is efficiently accessing public markets to fund its most promising therapeutic candidates. The decision to raise capital at this juncture ensures that the company can maintain momentum in liver-targeted disease programs without immediate reliance on short-term revenue. This strategy provides a buffer against the high costs associated with gene editing clinical trials and regulatory filing processes, positioning the firm to reach its next set of data readouts with a strengthened balance sheet.
Business Overview
Prime Medicine is a biotechnology firm specializing in Prime Editing, a versatile gene-editing technology designed to search and replace genetic sequences. This technology aims to correct the vast majority of known disease-causing mutations with high precision and minimal off-target effects. The company's current focus is primarily on hepatic and hematological conditions, with lead programs targeting Wilson disease and alpha-1 antitrypsin deficiency. Based in Cambridge, Massachusetts, Prime Medicine operates as an early-stage clinical player in the genetic medicine sector, competing with established CRISPR and base-editing firms to provide one-time curative therapies for complex genetic disorders.
Financial Context
Prior to the offering, Prime Medicine maintained a market capitalization of roughly $779.9 million. As a development-stage biopharmaceutical entity, the company reported annual revenue of $4.63 million, primarily derived from collaboration or research activities rather than commercial product sales. The anticipated net proceeds of $134.7 million represent a significant increase in available cash reserves, which is critical for a firm currently reporting quarterly revenue of $1.15 million. With a Relative Strength Index of 52.3, the stock has recently experienced neutral trading momentum, despite a significant 10.26 percent day change prior to the announcement.
Down 2.6% since our story on 12 Nov: $4.30 when we broke it → $4.19 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $3.83 |
|---|---|
| 20 Oct | $3.92 |
| 21 Oct | $3.81 |
| 22 Oct | $3.73 |
| 23 Oct | $3.67 |
| 26 Oct | $3.61 |
| 27 Oct | $4.35 |
| 28 Oct | $5.36 |
| 29 Oct | $5.24 |
| 30 Oct | $4.72 |
| 2 Nov | $4.44 |
| 3 Nov | $4.55 |
| 4 Nov | $4.97 |
| 5 Nov | $4.45 |
| 6 Nov | $4.65 |
| 9 Nov | $4.30 |
| 10 Nov | $3.90 |
| 11 Nov | $4.30 |
| 12 Nov | $3.89 |
| 13 Nov | $4.27 |
| 16 Nov | $4.19 |
| Share price | $4.30 |
|---|---|
| Market cap | $780M |
| Revenue (annual) | $5M |
| 1-month price change | +19.11% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Prime Medicine, Inc. announcing an underwritten public offering of common stock.
Track Prime Medicine, Inc. live
Get the next Prime Medicine, Inc. SEC filing seconds after it lands.



